Actavia Life Sciences, Inc. is a leukemia-focused biotechnology company. The Company is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. It develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	30.87L 27.09L 25.59L 23.32L 43.65L 30Cr 43.96L 3.06Cr 1.19Cr 15Cr 1.16Cr 1.13Cr 49Cr	P/E 2022	-1.98x	P/E 2023	-2x
Enterprise Value	32.23L 28.28L 26.71L 24.34L 45.57L 31Cr 45.9L 3.2Cr 1.24Cr 16Cr 1.21Cr 1.18Cr 51Cr	EV / Sales 2022	-	EV / Sales 2023	-
Free-Float	14.81%	Yield 2022 *	-	Yield 2023	-

20/24/20	Actavia Life Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
17/24/17	Actavia Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	CI
05/24/05	Actavia Life Sciences, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	CI
05/24/05	Actavia Life Sciences, Inc. Auditor Raises 'Going Concern' Doubt	CI
14/23/14	Rasna Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	CI
15/23/15	Rasna Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	CI
03/23/03	Rasna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	CI
10/23/10	Rasna Therapeutics, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	CI
09/23/09	Rasna Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
22/22/22	Rasna Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	CI
21/22/21	Rasna Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022	CI
16/22/16	Rasna Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2021	CI
10/22/10	Rasna Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI

11/24/11	Actavia Life Sciences : Change in Certifying Accountants - Form 8-K	PU
03/23/03	RASNA THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
10/23/10	RASNA THERAPEUTICS INC. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
24/23/24	Rasna Therapeutics : Certificate of Incorporation/Bylaws - Form 8-K	PU
24/23/24	RASNA THERAPEUTICS INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	AQ

Manager	Title	Age	Since
Keeren Shah DFI	Director of Finance/CFO	50	31/07/2020
Jules S. Jacob PRN	Corporate Officer/Principal	-	01/07/2017

Director	Title	Age	Since
John Brancaccio BRD	Director/Board Member	78	01/08/2016
Willy Simon CHM	Chairman	74	14/10/2020
Gary Jacob BRD	Director/Board Member	79	23/12/2020

Rasna Therapeutics, Inc. Share Price Other OTC

Stocks

RASP

US7538881068

Biotechnology & Medical Research

Valuation: Rasna Therapeutics, Inc.

Latest news: Rasna Therapeutics, Inc.

Press Releases: Rasna Therapeutics, Inc.

Quotes and Performance

Managers and Directors: Rasna Therapeutics, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RASNA THERAPEUTICS, INC.	-28.57%	-47.37%	-	-	4L
WUXI APPTEC CO., LTD.	-3.30%	+1.50%	+57.79%	+99.14%	7.23TCr
ARGENX SE	+1.25%	-3.01%	+37.83%	+87.66%	6.02TCr
WUXI BIOLOGICS (CAYMAN) INC.	+2.12%	+5.26%	+35.69%	+23.40%	2.77TCr
INSMED INCORPORATED	-3.06%	-1.81%	-14.01%	+357.24%	2.57TCr
BIONTECH SE	-0.75%	+2.56%	+0.45%	-3.28%	2.47TCr
GENMAB A/S	+0.40%	+0.75%	+23.72%	-11.33%	2.07TCr
PHARMAESSENTIA CORPORATION	-1.70%	-2.12%	+150.24%	+326.97%	1.51TCr
EXELIXIS, INC.	+0.36%	-0.34%	+48.98%	+167.40%	1.44TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.21%	+1.17%	-3.95%	+512.06%	1.42TCr
Average	-3.30%	+0.44%	+37.41%	+173.25%	3.06TCr
Weighted average by Cap.	-0.77%	+0.31%	+38.16%	+132.99%

	2022	2023
Net sales	-	-
Net income	-7L -6L -6L -5L -10L -6.58Cr -10L -68.09L -26.37L -3.36Cr -25.78L -25.22L -11Cr	-44.43L -38.98L -36.82L -33.55L -62.81L -43Cr -63.26L -4.41Cr -1.71Cr -22Cr -1.67Cr -1.63Cr -70Cr
Net Debt	2L 2L 1L 1L 3L 1.73Cr 3L 17.88L 7L 88.3L 7L 7L 2.84Cr	1L 1L 1L 1L 2L 1.3Cr 2L 13.49L 5L 66.59L 5L 5L 2.14Cr